NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) between February 6, 2024 to July 24, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Dhimant Patel v. Edwards Lifesciences Corporation, et al. (Case No. 8:24-cv-02221) has been commenced in the United States District ...

文章核心观点 - 医疗设备公司Edwards Lifescience (EW)的股价大涨6%,达到每股68.49美元,技术分析显示这是一个"强烈买入"的时机 [1] - 公司获得了其经导管三尖瓣置换(TTVR)设备的商业批准,这是一个重要里程碑 [1] - TTVR设备是公司最大的收入来源,商业批准意味着销售范围将更广泛 [1] 公司业务分析 - 公司有4个业务分部:经导管主动脉瓣置换(TAVR)占64.61%销售额、外科结构性心脏占16.64%、关键护理占15.46%、经导管二尖瓣和三尖瓣治疗占3.29% [1] - TAVR作为最大收入来源,有利好消息可能带来未来整体销售的改善 [2] - 公司计划在2025年出售关键护理业务,这将降低公司利润率和收益 [3] - 但如果TAVR这一最大收入来源能够增加销售,可以弥补关键护理业务剥离带来的收入下降 [3] - 公司在无症状主动脉瓣狭窄领域的TAVR早期试验有望获得积极结果,这也支撑了最大收入来源 [3]

Edwards Lifesciences' (EW) strategic decision to divest its Critical Care segment aligns with its vision to create a comprehensive portfolio for structural heart disease. Innovations such as the RESILLIA technology enhance the performance of the company's TAVR (Transcatheter Aortic Valve Replacement) business. Additionally, progress within the TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio instils optimism. However, adverse macroeconomic impacts and currency fluctuations raise concerns for Ed ...

In my opinion, companies that have a stable position in their market and competitive advantages are an interesting investment when they face temporary problems that can be solved. And Edwards Lifesciences Corporation ( My primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for ...

Edwards Lifesciences (EW) has completed the sale of its Critical Care product group to Becton, Dickinson and Company (BDX) for $4.2 billion in an all-cash transaction. The divestiture was first announced earlier in June 2024, replacing the previous plan for a tax-free spin-off of the segment. The company will use the net proceeds from the sale to fund strategic initiatives, including the previously announced acquisitions and share repurchases. Investors' sentiment was bearish immediately after the news rele ...

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that, further to its news releases of August 16, 2024 and August 29, 2024, the special distribution to holders of common shares of the Company ("Shareholders") by way of a return of capital, in the amount of $0.03 per common share of the Company, for an aggregate distribution amount of $ 2,714,569.95 (the "Distribution"), will be paid by the Company's ...

At the European Society of Cardiology Congress 2024, Edwards Lifesciences (EW) announced the results from the RHEIA Trial — the first-ever study focused exclusively on women receiving transcatheter aortic valve implantation (TAVI). The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with those receiving surgical aortic valve replacement (SAVR). The latest development will strongly boost the company's Transcatheter Aortic Valve Replacement (TAV ...

. . . East West Petroleum Announces Cash Distribution to Shareholders by Way of Return of Capital August 29, 2024 7:00 AM EDT | Source: East West Petroleum Corp. Vancouver, British Columbia--(Newsfile Corp. - August 29, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that, further to its news release of August 16, 2024, it will distribute to holders of common shares of the Company ("Shareholders") by way of a return of capital, $0.03 per common share of the ...